These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 23593654)

  • 1. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
    Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
    Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
    Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
    Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
    Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
    Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer.
    Shiota M; Yokomizo A; Takeuchi A; Itsumi M; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Prostate; 2014 Jun; 74(9):959-69. PubMed ID: 24740858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition.
    Astanehe A; Finkbeiner MR; Krzywinski M; Fotovati A; Dhillon J; Berquin IM; Mills GB; Marra MA; Dunn SE
    Oncogene; 2012 Oct; 31(41):4434-46. PubMed ID: 22249268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models.
    Sechi M; Lall RK; Afolabi SO; Singh A; Joshi DC; Chiu SY; Mukhtar H; Syed DN
    Sci Rep; 2018 Oct; 8(1):15726. PubMed ID: 30356079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous Targeting of RSK and AKT Efficiently Inhibits YB-1-Mediated Repair of Ionizing Radiation-Induced DNA Double-Strand Breaks in Breast Cancer Cells.
    Lettau K; Zips D; Toulany M
    Int J Radiat Oncol Biol Phys; 2021 Feb; 109(2):567-580. PubMed ID: 32931865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular Signal-regulated Kinase (ERK)-dependent Phosphorylation of Y-Box-binding Protein 1 (YB-1) Enhances Gene Expression in Granulosa Cells in Response to Follicle-stimulating Hormone (FSH).
    Donaubauer EM; Hunzicker-Dunn ME
    J Biol Chem; 2016 Jun; 291(23):12145-60. PubMed ID: 27080258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.
    Law JH; Li Y; To K; Wang M; Astanehe A; Lambie K; Dhillon J; Jones SJ; Gleave ME; Eaves CJ; Dunn SE
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
    Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
    Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
    Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
    Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
    Ludwik KA; Campbell JP; Li M; Li Y; Sandusky ZM; Pasic L; Sowder ME; Brenin DR; Pietenpol JA; O'Doherty GA; Lannigan DA
    Mol Cancer Ther; 2016 Nov; 15(11):2598-2608. PubMed ID: 27528706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
    Hu K; Law JH; Fotovati A; Dunn SE
    Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.
    Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B
    Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.
    To K; Fotovati A; Reipas KM; Law JH; Hu K; Wang J; Astanehe A; Davies AH; Lee L; Stratford AL; Raouf A; Johnson P; Berquin IM; Royer HD; Eaves CJ; Dunn SE
    Cancer Res; 2010 Apr; 70(7):2840-51. PubMed ID: 20332234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.
    Cuesta R; Holz MK
    Oncotarget; 2016 May; 7(19):27567-83. PubMed ID: 27028868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stress-Induced Phosphorylation of Nuclear YB-1 Depends on Nuclear Trafficking of p90 Ribosomal S6 Kinase.
    Tiwari A; Rebholz S; Maier E; Dehghan Harati M; Zips D; Sers C; Rodemann HP; Toulany M
    Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30126195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells.
    Davies AH; Reipas K; Hu K; Berns R; Firmino N; Stratford AL; Dunn SE
    Oncotarget; 2015 Aug; 6(24):20570-7. PubMed ID: 26011941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma.
    Pambid MR; Berns R; Adomat HH; Hu K; Triscott J; Maurer N; Zisman N; Ramaswamy V; Hawkins CE; Taylor MD; Dunham C; Guns E; Dunn SE
    Pediatr Blood Cancer; 2014 Jan; 61(1):107-15. PubMed ID: 23940083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.
    Dhillon J; Astanehe A; Lee C; Fotovati A; Hu K; Dunn SE
    Oncogene; 2010 Nov; 29(47):6294-300. PubMed ID: 20802512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.